Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00039858 · ClinicalTrials.gov registry record · Phase 4
Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin
A Phase 4 study of Thrombosis and Thrombocytopenia, sponsored by Encysive Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 24
- Enrollment target
- 13
- Study locations
NCT00039858: Completed Phase 4 study of Thrombosis and Thrombocytopenia, sponsored by Encysive Pharmaceuticals.
NCT00039858 is a Phase 4 study of Thrombosis and Thrombocytopenia that has completed, run by Encysive Pharmaceuticals. The registered enrollment target is 24 participants, below the 469-participant average among 28 other Thrombosis trials with a reported enrollment target (95% lower). The trial reports 13 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00039858, a Phase 4 study of Thrombosis and Thrombocytopenia, has completed, sponsored by Encysive Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 24 participants
- Enrollment target
- 13
- Study locations
Study Summary
The purpose of this study is to evaluate the safe and effective dose of Argatroban for prophylaxis and/or treatment of thrombosis in pediatric patients with current or previous diagnosis of heparin-induced thrombocytopenia (HIT) and thrombosis syndrome (HITTS), or who in the opinion of the investigator require alternative anticoagulation due to an underlying condition.
Conditions Studied
Interventions
- DRUG Argatroban
Study Locations (13)
Illinois
- Rush University Medical Center - Chicago
- University of Chicago Children's Hospital - Chicago
- Children's Hospital of Illinois - Peoria
California
- Mattel Children's Hospital at UCLA - Los Angeles
- Children's Hospital of Orange County - Orange
Kentucky
- Kosair Children's Hospital, University of Louisville - Louisville
Massachusetts
- Children's Hospital of Boston - Boston
Michigan
- Michigan Congenital Heart Center - Ann Arbor
Ohio
- Rainbow Babies at Children's Hospital - Cleveland
Oregon
- Oregon Health & Science University - Portland
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2003-09 |
| Est. Completion | 2006-03 |
| Phase | Phase 4 |
What the finished NCT00039858 record still lists
NCT00039858 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 469-participant average among 28 other Thrombosis trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Thrombosis appearing as the primary indexed condition, and to 1 intervention - of which Argatroban is the first listed.
NCT00039858 lists 13 locations in 10 states (Illinois, California, Kentucky).
Frequently Asked Questions
What is clinical trial NCT00039858 about?
NCT00039858 is a clinical study titled "Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin". The purpose of this study is to evaluate the safe and effective dose of Argatroban for prophylaxis and/or treatment of thrombosis in pediatric patients with current or previous diagnosis of heparin-induced thrombocytopenia (HIT) and thrombosis syndrome (HITTS), or who in the opinion of the investiga...
What is the current status of trial NCT00039858?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 24 participants. The study started on 2003-09. Estimated completion is 2006-03.
What conditions does trial NCT00039858 study?
This clinical trial studies the following conditions: Thrombosis, Thrombocytopenia.
What interventions are being tested in trial NCT00039858?
The interventions under investigation include: Argatroban (DRUG).
Who is sponsoring clinical trial NCT00039858?
This trial is sponsored by Encysive Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00039858 being conducted?
This trial has 13 study locations across California, Illinois, Kentucky, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thrombosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00039858's enrollment target sits among peer trials
24 18th of 28 higher than 10 of 28 other Thrombosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Thrombosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Antithrombotic Activities of Sotagliflozin vs. Empagliflozin
ACTIVE NOT RECRUITING · Phase 4
-
Apixaban for Secondary Prevention of Thromboembolism Among Patients With AntiphosPholipid Syndrome
COMPLETED · Phase 4
-
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
RECRUITING
-
Positron Emission Tomography (PET) Imaging of Thrombosis
RECRUITING · Phase 1
-
Pharmacogenomics of Warfarin in Hispanics and Latinos
RECRUITING
-
Neonatal Platelet Transfusion Threshold Trial
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia